Qualigen Therapeutics Inc (QLGN)
NASDAQ:QLGN

Qualigen Therapeutics (QLGN) Stock Price & Analysis

617 Followers

QLGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.14 - $1.26
Previous Close$0.25
Volume915.25K
Average Volume (3M)13.05M
Market Cap
$2.88M
Enterprise Value$3.80M
Total Cash (Recent Filing)$100.00K
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)
Beta0.76
Aug 13, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding6,307,371
10 Day Avg. Volume6,076,412
30 Day Avg. Volume13,052,179
Standard Deviation0.36
R-Squared0.00948
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-0.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

84.20%1.07%0.52%14.21%
84.20%
Insiders
0.52% Other Institutional Investors
14.21% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

QLGN FAQ

What was Qualigen Therapeutics Inc’s price range in the past 12 months?
Qualigen Therapeutics Inc lowest stock price was $0.14 and its highest was $1.26 in the past 12 months.
    What is Qualigen Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Qualigen Therapeutics Inc’s upcoming earnings report date?
    Qualigen Therapeutics Inc’s upcoming earnings report date is Aug 13, 2024 which is in 17 days.
      How were Qualigen Therapeutics Inc’s earnings last quarter?
      Currently, no data Available
      Is Qualigen Therapeutics Inc overvalued?
      According to Wall Street analysts Qualigen Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Qualigen Therapeutics Inc pay dividends?
        Qualigen Therapeutics Inc does not currently pay dividends.
        What is Qualigen Therapeutics Inc’s EPS estimate?
        Qualigen Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Qualigen Therapeutics Inc have?
        Qualigen Therapeutics Inc has 11,382,830 shares outstanding.
          What happened to Qualigen Therapeutics Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Qualigen Therapeutics Inc?
          Currently, no hedge funds are holding shares in QLGN
          ---

          Qualigen Therapeutics Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -74.36%
          12-Months-Change

          Fundamentals

          Return on Equity
          -1656.23%
          Trailing 12-Months
          Asset Growth
          -93.70%
          Trailing 12-Months

          Company Description

          Qualigen Therapeutics Inc

          Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Agenus
          Alimera
          Aileron Therapeutics
          Ampio Pharmaceuticals
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis